Sumitomo Pharma Co. Ltd
Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson's disease, type 2 diabetes, advanced prostate cancer, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, an… Read more
Sumitomo Pharma Co. Ltd (SMDPY) - Total Liabilities
Latest total liabilities as of December 2025: $526.94 Billion USD
Based on the latest financial reports, Sumitomo Pharma Co. Ltd (SMDPY) has total liabilities worth $526.94 Billion USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sumitomo Pharma Co. Ltd - Total Liabilities Trend (2005–2025)
This chart illustrates how Sumitomo Pharma Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Sumitomo Pharma Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Sumitomo Pharma Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bright Smart Securities & Commodities Group Limited
F:0BX
|
Germany | €8.35 Billion |
|
Nos SGPS SA
LSE:0J1Z
|
UK | €2.17 Billion |
|
AIMA Technology Group Co Ltd
SHG:603529
|
China | CN¥17.40 Billion |
|
Qinchuan Machine Tool & Tool Group Share Co Ltd
SHE:000837
|
China | CN¥4.36 Billion |
|
Altarea
LSE:0IRK
|
UK | €4.88 Billion |
|
ZHEJIANG ASIA-PACIFIC MECHANICAL & ELECTRONIC CO LTD
SHE:002284
|
China | CN¥4.79 Billion |
|
United Parks & Resorts Inc
NYSE:PRKS
|
USA | $3.05 Billion |
|
ARS Pharmaceuticals, Inc
NASDAQ:SPRY
|
USA | $225.15 Million |
Liability Composition Analysis (2005–2025)
This chart breaks down Sumitomo Pharma Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.82 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.65 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sumitomo Pharma Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sumitomo Pharma Co. Ltd (2005–2025)
The table below shows the annual total liabilities of Sumitomo Pharma Co. Ltd from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $573.12 Billion | -23.72% |
| 2024-03-31 | $751.37 Billion | +3.22% |
| 2023-03-31 | $727.96 Billion | +14.74% |
| 2022-03-31 | $634.44 Billion | -3.87% |
| 2021-03-31 | $659.95 Billion | +6.31% |
| 2020-03-31 | $620.77 Billion | +84.44% |
| 2019-03-31 | $336.58 Billion | -5.71% |
| 2018-03-31 | $356.96 Billion | +7.10% |
| 2017-03-31 | $333.29 Billion | +27.58% |
| 2016-03-31 | $261.24 Billion | +0.26% |
| 2015-03-31 | $260.56 Billion | +0.03% |
| 2014-03-31 | $260.49 Billion | +0.98% |
| 2013-03-31 | $257.97 Billion | +7.41% |
| 2012-03-31 | $240.18 Billion | -9.67% |
| 2011-03-31 | $265.88 Billion | -6.13% |
| 2010-03-31 | $283.26 Billion | +324.05% |
| 2009-03-31 | $66.80 Billion | -17.97% |
| 2008-03-31 | $81.43 Billion | +6.41% |
| 2007-03-31 | $76.52 Billion | -26.66% |
| 2006-03-31 | $104.33 Billion | +58.09% |
| 2005-03-31 | $66.00 Billion | -- |